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Overdiagnosis and overtreatment have serious implications for
individuals, healthcare systems, and society,1 2 and effective
strategies are urgently needed to help the public, clinicians, and
policy makers address this problem. Communication about
overdiagnosis has been highlighted as essential for moving
forward but presents several challenges, such as the potential
to confuse the public, undermine trust, and adversely affect
people who already have a diagnosis. Various communication
based strategies offer real promise; we describe what is known
and what we need to know to communicate effectively and
safely about overdiagnosis and overtreatment.
What are the key messages to be
communicated?
Understanding of overdiagnosis among the general public and
health professionals is limited, so it is essential to communicate
what it means for individuals, the health system, and society
(box 1). By definition, overdiagnosis will not improve prognosis
andwill probably harm individuals (for example, by unnecessary
intervention) or society (opportunity costs). For individuals, it
is important to communicate the nature (physical or
psychological), likelihood, and duration of the harms. For
societies with free public healthcare, the financial strain and
opportunity cost are usually at system level—resources wasted
on unnecessary tests and treatments are unavailable for people
in greater need. But in private healthcare systems, overdiagnosis
can be a huge personal financial burden, even for those with
insurance.
Communication is further complicated because it is usually
impossible to know whether an individual has been
overdiagnosed or benefited from the diagnosis—overdiagnosis
can only be observed at the aggregate level. Recent efforts to
communicate the concept and likelihood of overdiagnosis in
breast screening have had some success, albeit with much room
for improvement. When given a patient decision aid including
an infographic and icon array (figure⇓), 29% of women
understood both the concept and quantitative outcomes of breast
screening (including deaths avoided, false positive results, and
overdiagnosis); 59% of women understood the conceptual
information alone.3
Communication based strategies to
mitigate overdiagnosis
Several communication based strategies have been applied in
the areas of overtesting and overtreatment and directed at
individual, community, or policy levels (box 2).
Strategies for individuals
Shared decision making is a consultation process where a
clinician and patient jointly make a health decision. It changes
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Box 1: Overdiagnosis and its consequences1 2
Overdiagnosis occurs when a diagnosis is “correct” according to current professional standards but when the diagnosis or associated
treatment has a low probability of benefiting the person diagnosed.2 It is caused by a range of factors such as:
• Use of increasingly sensitive tests that identify abnormalities that are indolent, non-progressive, or regressive (overdetection)
• Expanded definitions of disease—for example, attention-deficit/hyperactivity disorder and dementia—and lowering of disease thresholds,
such as osteoporosis (overdefinition)
• Creation of pseudodiseases (also called disease mongering), such as low testosterone and restless leg syndrome
• Clinicians’ fear of missing a diagnosis or litigation
• Public enthusiasm for screening or testing and desire for reassurance
• Financial incentives
Potential consequences of overdiagnosis
• Psychological and behavioural effects of disease labelling
• Physical harms and side effects of unnecessary tests or treatment
• Quality of life affected by unnecessary treatment
• Hassles of unnecessary tests and treatments
• Increased financial costs to individuals
• Wasted resources and opportunity costs to the health system
• Overmedicalisation of society
the way decisions are framed by identifying that there is a
decision to be made (not an obligatory test or default treatment),
and explaining the range of options available and their benefits
and harms. It also involves deciding with patients “what is most
important to them” in terms of their values, preferences, and
circumstances.4 Importantly, the option of doing nothing or
active surveillance can be discussed as a deliberate or positive
action5 to counter people’s bias for tests and treatment, especially
in cancer.6Consumer led interventions that teach patients to ask
about benefits and harms of different options have shown some
success.7 Shared decision making is increasingly part of clinical
training, often combined with evidence based healthcare,8 and
this should be enhanced to include understanding and
communicating about overdiagnosis.
Patient decision aids support shared decision making. High
quality evidence from 115 trials shows that they improve
patients’ knowledge and understanding of options and their
risks and benefits, and increase consistency between patients’
values and choices.9 Decision aids have successfully informed
women about overdiagnosis in breast screening,3 reduced men’s
desire for prostate specific antigen (PSA) testing10 or surgical
management for prostate cancer, and reduced preferences for
potentially unnecessary elective surgery.9 A trial of a decision
aid communicating overdiagnosis in breast screening (879
women approaching age 50) increased informed choice
compared with controls and did not increase anxiety; worry
about breast cancer decreased (box 2).3A pilot study of a breast
screening decision aid for women over 75 years (n=45) including
information on overdiagnosis had similar findings.11 12However,
information on the harms of overdiagnosis and overtreatment
is rarely presented.13 14Consumers consistently overestimate the
benefits of screening, tests, and treatments and underestimate
the harms,13 and although shared decision making is widely
espoused, it is not often implemented.15
Strategies for communities
Mass media and direct to consumer campaigns can influence
large numbers of people simultaneously and promote sustained
beneficial changes in behaviour.16 For example, a mass media
campaign about back pain, driven partly by concerns about
unnecessary back imaging, changed both community and general
practitioner beliefs about management, resulting in reduced
imaging, work insurance claims, and healthcare usage.17 Scaled
down versions of the programme have been replicated in several
countries.16 Other important initiatives include the Choosing
Wisely campaign, now operating in nine countries (www.
choosingwisely.org), and the UK’s “do not do” list.
Policy directed strategies
Deliberative democratic methods (such as community juries)
support policy decisions by gathering informed public responses
about disputed issues, such as what services are available or
reimbursed by health funds. Because overdiagnosis is
scientifically and politically contested, this topic is ideal for
deliberative democratic methods. Deliberative methods must
meet exacting standards and are time consuming.18 Community
juries have considered PSA testing in Australia19 20 and
mammographic screening in New Zealand, where participants
changed their recommendation at least partly because of
potential harms from overdiagnosis.21 Disseminating findings
from juries could enhance community health literacy, leading
to better informed citizens and more transparent decision
making.
Changing terminology:Behaviours can be influenced bymedical
terminology, and changing the names for medical conditions
may help reduce the effect of overdiagnosis. In one study,
describing ductal carcinoma in situ as “non-invasive cancer”
resulted in 13-16% more women choosing surgical treatment
(rather than medication or active surveillance) compared with
calling it a “breast lesion” or “abnormal cells.”22 Similar findings
were reported in Australia.23 24 Independent experts convened
by the US National Cancer Institute25 and National Institute of
Health have proposed dropping the word “cancer” entirely in
this case, arguing for it to be reserved for lesions likely to
progress if untreated.25 26 Similar arguments exist for thyroid
and prostate cancer,27 but effects of disease labels extend beyond
cancer. Parents were more likely to accept medication when
“gastro-oesophageal reflux disease” (compared with no label)
was used to describe excessive irritability in infants, even when
told the drugs would not control the symptoms.28
Potential challenges to effective
communication
Low levels of awareness: Awareness of overdiagnosis is low,
particularly for cancer screening with few people understanding
overdiagnosis of cancer is even possible.29 30 In one study, 18%
of Australian men and only 10% of women said they had been
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;352:i348 doi: 10.1136/bmj.i348 (Published 5 February 2016) Page 2 of 5
ANALYSIS
Box 2: Examples of effective communication strategies for overdiagnosis or overtreatment
Community back pain campaign (three year campaign 1997-99)17
• Significant improvements in community (n=4730) beliefs about back pain over three years in Victoria (where campaign was run) versus
New South Wales (no campaign)
• General practitioners’(n=2556) knowledge improved—for example, time when patients can to return to work, not prescribing complete
bed rest. In a patient scenario, GPs in Victoria were 2.51 times less likely to order tests for acute low back pain and 0.40 times as
likely to order lumbosacral radiographs. Over the duration of the campaign insurance claims for back pain reduced by 15%
Patient decision aids9
• Cochrane review of 115 randomised controlled trials reported that decision aids reduced number of people choosing major elective
surgery in favour of more conservative options (relative risk 0.79) and reduced number of men choosing PSA testing (RR 0.87) in
nine studies
• A randomised trial of a decision aid for women approaching 50 years (n=879), which explicitly explained the concept of overdiagnosis
and presented quantitative information on its likelihood, found that it increased informed choice by 9% (intervention24% v control
15%), reduced intentions to screen by 13% (74% v 87%)3
Changing disease terminology
• Study of 394 women compared the commonly used cancer term for ductal carcinoma in situ (non-invasive cancer) with non-cancer
terms (breast lesion, abnormal cells). Results showed 47% preferred surgery when cancer term was used compared with 34% and
31% respectively22
Citizen juries
• 27 men randomly allocated to PSA screening community jury (12 men) or control (15 men). The jury concluded that the Australian
government should not invest in PSA testing and recommended an education programme for GPs with better quality and consistent
information about PSA for doctors and patients. After the jury, men had significantly lower intentions to screen compared with controls24
told about overdiagnosis in screening for prostate and breast
cancer respectively.31 Similarly, a US survey reported only 9.5%
of men and women (aged 50-69 years) said they had been
informed about overdiagnosis when discussing cancer
screening.32 Further US and UK studies reported that only about
half of respondents had heard of “cancers that grow so slowly
that they are unlikely to cause [you] problems in [your]
lifetime.”33 34 There are few publications reporting clinician
awareness, but one recent survey among 126 university affiliated
clinicians in the US found 28% listed overdiagnosis as a
potential harm of PSA testing, and 56% listed unnecessary
treatment.35
Cognitive biases and counterintuitive messages: Longstanding,
prominent public health messages have emphasised the benefits
and ignored the harms of early diagnosis for many diseases.36 37
This makes the concept of overdiagnosis unfamiliar,
counterintuitive, and difficult to understand. There is widespread
faith in the importance of early detection,38 39 and people may
choose cancer screening because it is the apparent default
decision, even if their informed preferences would be
different.40-42 Furthermore, when people are predisposed towards
an intervention, they may perceive benefits to be high and risks
low, even when explicitly told otherwise.43 Suggesting a
reduction in tests that are popular with the public can provoke
emotionally charged, even hostile responses,44 reflecting
cognitive dissonance.45
Uncertainty and trust: Intolerance of uncertainty and anxiety
about missing rare cases underpin much medical excess.46
Communicating about overdiagnosis requires us to acknowledge
the inherent uncertainty in the size and extent of the problem
and its consequences. These issues are often hotly contested.47
Communicating uncertainty adds complexity and may lead to
confusion and avoidance of decision making48 and can
undermine trust in the healthcare provider.49 However, distrust
can also arise when patients discover that information about
harms has been withheld. Clinicians often avoid discussing
uncertainty with patients,48 but studies of breast and prostate
screening show that people want to be told about
overdiagnosis.19 29
Vested interests and persuasive communication: Vested interests
may influence how information is presented in the media and
the scientific arena. Pharmaceutical and device manufacturers
have direct interests in maximising product sales. Industry
funded disease awareness campaigns often increase the numbers
of people portrayed as patients.50Narrowing the boundaries that
define disease or raising diagnostic thresholds is a threat to
turnover, profit, and professional interests.51 Similarly patient
advocacy groups, often also industry funded, can have interests
in portraying their condition as widespread, severe, and treatable
to optimise media, professional, and policy attention and to
attract resources.52 Politicians too have seen mileage in
supporting screening programmes without offering more
nuanced assessments of their benefits and harms, including risks
of overdiagnosis.53
Further research directions
We need studies about what the public, patients, and clinicians
currently know, understand, and want to know about
overdiagnosis and their attitudes, reactions, and choices when
provided with such information. Then we can research effective
communication—how to increase understanding among all
parties and the effectiveness and acceptability of such strategies.
Once effective interventions are identified, we need to
understand how to implement them within healthcare systems
that currently reward overdiagnosis. However, research must
also consider potential harms of communicating overdiagnosis,
and herein lies the tightrope. Possible harms include cognitively
overburdening and confusing the public, adversely affecting
patients already diagnosed and treated, and creating distrust in
conventional medicine.29 A careful evidence based approach is
essential.
Achieving widespread understanding about overdiagnosis will
take time, but we have some tools to move forward. Given that
high health anxiety is largely a consequence of the health system
itself, the health community must be patient with and
sympathetic towards those who do not share this concern about
overdiagnosis. Successful communication that empowers the
public, patients, clinicians, and policymakers to think differently
about overdiagnosis will help support more sustainable
healthcare for all.
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Key messages
Overdiagnosis provides no benefits to patients and is a challenge to the sustainability of modern healthcare systems
Communication based strategies could help reduce overdiagnosis and its negative impact on individuals and health systems
Mass media education, shared decision making, terminology changes for disease states, and deliberative methods (juries) all have
potential as effective communication strategies
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Figure
Infographic and icon array explaining overdiagnosis in breast screening in a patient decision aid developed by Hersch et
al3
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